Institute Of Mother And Child, Warsaw, Poland

This study tests the drug regorafenib in 30 patients aged 9 to 21 with bone cancers (osteosarcoma or Ewing sarcoma) that have not responded to standard therapy. The goal is to see if the drug can help control the disease and improve survival, while also checking its safety. The a…